文献速递临床血液与体液分子诊断质量管理与危急值

干细胞来源体外生产血小板与巨核细胞的实验室评估及临床前景

Laboratory Assessment and Clinical Outlook for Ex Vivo-Produced Human Platelets and Megakaryocytes from Stem Cell Sources.
PubMed 文献 · Ann Lab Med · 2026-04-27

本文综述了干细胞来源体外血小板生产的现状与未来方向,涵盖干细胞来源、制造工艺创新、质量控制方法及从实验室概念到临床现实的转化进程。首批人体临床试验已共同确立iPSC来源血小板输注的安全性,并凸显了实现与供者血小板相当疗效的转化挑战。

要点

  • 首批人体临床试验已共同确立iPSC来源血小板输注的安全性
  • 剩余挑战包括降低成本与优化血小板产品的体内循环

核心结论

  • 干细胞来源体外血小板生产有望将依赖献血者的脆弱体系转变为按需生产标准化、无病原体且通用兼容血小板的体系。
  • 初步实施可能聚焦于高价值应用,如为同种免疫患者输注,之后再扩大应用范围。

研究设计与样本

  • 本文为批判性综述,聚焦干细胞来源、制造创新、QC方法及从实验室概念到临床现实的进展。

主要发现

  • 综合质量框架涵盖细胞与分子表征、功能试验及体内验证。
  • 首批人体临床试验共同确立iPSC来源血小板输注的安全性,并凸显实现与供者相当疗效的转化挑战。

关键数值与推荐

  • 综合质量框架涵盖细胞与分子表征、功能试验和体内验证。

临床怎么用

  • 临床初期可优先面向同种免疫患者等高价值场景应用体外生产血小板,长期目标是替代依赖献血者的供应体系。

局限性

  • 剩余挑战包括降低成本和优化血小板产品的体内循环。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Platelet transfusions are essential for managing thrombocytopenia but have critical limitations, including a 5-7-day shelf-life causing wastage, alloimmune refractoriness in chronically transfused patients, and vulnerability to supply disruptions. Ex vivo platelet production from stem cells represents a transformative solution, evolving from initial hematopoietic stem cell approaches to induced pluripotent stem cell platforms with unlimited expansion and genetic tractability for universal platelet products. We critically reviewed the state and future trajectory of ex vivo platelet production, focusing on stem cell sources, manufacturing innovations, QC methods, and progression from laboratory concept to clinical reality. Key advances include immortalized megakaryocyte progenitor cell lines for scalable manufacturing; turbulence-based bioreactors that harness physiological shear stress to produce over 100 billion platelets/run; and comprehensive quality frameworks spanning cellular and molecular characterization, functional assays, and in vivo validation. We comparatively analyzed pioneering first-in-human clinical trials that collectively established the safety of iPSC-derived platelet transfusion and highlighted the translational challenges of achieving donor-comparable efficacy. We also highlighted the evolving corporate landscape, wherein companies pursue commercialization alongside national initiatives, including Korea's 15-yr artificial blood program. Convergence between biological insight, engineering innovation, and sustained investment suggests that ex vivo platelet production can transform transfusion medicine. Remaining challenges include reducing costs and optimizing in vivo circulation of platelet products. Initial implementation will likely focus on high-value applications, such as transfusion for alloimmunized patients, before broader adoption. The long-term goal is to replace the vulnerable donor-dependent system with on-demand production of standardized, pathogen-free, and universally compatible platelets.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Kim KM, Albaira KI, Cho YG, et al. Laboratory Assessment and Clinical Outlook for Ex Vivo-Produced Human Platelets and Megakaryocytes from Stem Cell Sources. Ann Lab Med. 2026. PMID: 42037133. doi:10.3343/alm.2025.0687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。